• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Large owner Third Rock Ventures Iv, L.P. disposed of 1,600,000 shares (SEC Form 4)

    11/5/25 4:15:08 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MAZE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Third Rock Ventures IV, L.P.

    (Last) (First) (Middle)
    C/O THIRD ROCK VENTURES, LLC
    201 BROOKLINE AVE, SUITE 1401

    (Street)
    BOSTON MA 02215

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Maze Therapeutics, Inc. [ MAZE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    11/04/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 11/04/2025 J(1) 1,600,000 D (1) 4,473,958 D(2)(4)
    Common Stock 950,800 I See Footnotes(3)(4)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Third Rock Ventures IV, L.P.

    (Last) (First) (Middle)
    C/O THIRD ROCK VENTURES, LLC
    201 BROOKLINE AVE, SUITE 1401

    (Street)
    BOSTON MA 02215

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Third Rock Ventures GP IV, L.P.

    (Last) (First) (Middle)
    C/O THIRD ROCK VENTURES, LLC
    201 BROOKLINE AVE, SUITE 1401

    (Street)
    BOSTON MA 02215

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    TRV GP IV, LLC

    (Last) (First) (Middle)
    C/O THIRD ROCK VENTURES, LLC
    201 BROOKLINE AVE, SUITE 1401

    (Street)
    BOSTON MA 02215

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Third Rock Ventures V, L.P.

    (Last) (First) (Middle)
    C/O THIRD ROCK VENTURES, LLC
    201 BROOKLINE AVE, SUITE 1401

    (Street)
    BOSTON MA 02215

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    Third Rock Ventures GP V, LP

    (Last) (First) (Middle)
    C/O THIRD ROCK VENTURES, LLC
    201 BROOKLINE AVE, SUITE 1401

    (Street)
    BOSTON MA 02215

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    1. Name and Address of Reporting Person*
    TRV GP V, LLC

    (Last) (First) (Middle)
    C/O THIRD ROCK VENTURES, LLC
    201 BROOKLINE AVE, SUITE 1401

    (Street)
    BOSTON MA 02215

    (City) (State) (Zip)

    Relationship of Reporting Person(s) to Issuer
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    Explanation of Responses:
    1. On November 4, 2025, Third Rock Ventures IV, L.P. ("TRV IV ") distributed, for no consideration, 1,600,000 shares of Common Stock of the Issuer (the "Shares") to its limited partners and to Third Rock Ventures GP IV, L.P. ("TRV GP IV "), the general partner of TRV IV, representing each such partner's pro rata interest in such Shares. On the same date, TRV GP IV distributed, for no consideration, the Shares it received in the distribution by TRV IV to its partners, representing each such partner's pro rata interest in such Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
    2. The shares are held directly by TRV IV. The general partner of TRV IV is TRV GP IV. The general partner of TRV GP IV is TRV GP IV LLC. Each of TRV GP IV, and TRV GP IV LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
    3. The shares are held directly by Third Rock Ventures V, L.P. ("TRV V"). The general partner of TRV V is Third Rock Ventures GP V, L.P. ("TRV GP V"). The general partner of TRV GP V is TRV GP V, LLC ("TRV GP V LLC"). Each of TRV GP V, and TRV GP V LLC, disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, if any, and this report shall not be deemed an admission that it is the beneficial owner of such shares.
    4. Each of Reporting Persons disclaims the existence of a Section 13(d) "group" as between the TRV IV related parties and the TRV V related parties and this report shall not be deemed an admission that any of such parties is or may be part of such a group with any of the other parties.
    /s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P., general partner of Third Rock Ventures IV, L.P. 11/05/2025
    /s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC, general partner of Third Rock Ventures GP IV, L.P. 11/05/2025
    /s/ Kevin Gillis, Chief Operating Officer of TRV GP IV, LLC 11/05/2025
    /s/ Kevin Gillis, Chief Operating Officer of TRV GP V, LLC, general partner of Third Rock Ventures GP V, L.P., general partner of Third Rock Ventures V, L.P. 11/05/2025
    /s/ Kevin Gillis, Chief Operating Officer of TRV GP V, LLC, general partner of Third Rock Ventures GP V, L.P. 11/05/2025
    /s/ Kevin Gillis, Chief Operating Officer of TRV GP V, LLC 11/05/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $MAZE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MAZE

    DatePrice TargetRatingAnalyst
    11/14/2025Outperform
    Raymond James
    9/2/2025$30.00Buy
    BTIG Research
    7/23/2025$34.00Buy
    H.C. Wainwright
    7/8/2025$17.00Outperform
    Wedbush
    More analyst ratings

    $MAZE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Raymond James initiated coverage on Maze Therapeutics

    Raymond James initiated coverage of Maze Therapeutics with a rating of Outperform

    11/14/25 10:01:27 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BTIG Research initiated coverage on Maze Therapeutics with a new price target

    BTIG Research initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $30.00

    9/2/25 8:38:37 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Maze Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Maze Therapeutics with a rating of Buy and set a new price target of $34.00

    7/23/25 7:53:40 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MAZE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

    First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD); topline data for initial patients expected by the end of Q1 2026 Strong balance sheet with $383.9 million in cash, cash equivalents and marketable securities following oversubscribed private placement; cash runway into 2028 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developin

    11/6/25 4:01:00 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maze Therapeutics to Participate in Four Upcoming Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in four upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference; fireside chat on Tuesday, November 11, 2025, at 9:30 a.m. ETTD Cowen Immunology & Inflammation Summit; fireside chat on Thursday, November 13, 2025, at 2:00 p.m. ETJefferies Global Healthcare Conference in London; presentation on Thursday, November 20, 2025, at 12:00 p.m. GMT / 7:00 a.m. ET8th Annual Eve

    11/4/25 7:00:00 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

    SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the Board. "I am honored to assume the role of Chairman of the Board at this pivotal moment for Maze Therapeutics," said Mr. Hoppenot. "With encouraging first-in-human data for MZE782, an oversubscribed $150 million private placement, and important clinical milestones ahead, including the advancement of M

    10/6/25 7:00:50 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MAZE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Third Rock Ventures Iv, L.P. disposed of 1,600,000 shares (SEC Form 4)

    4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

    11/5/25 4:15:08 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Homcy Charles J gifted 28,423 shares, decreasing direct ownership by 49% to 29,624 units (SEC Form 4)

    4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

    10/27/25 4:46:23 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Director Hoppenot Herve

    4 - Maze Therapeutics, Inc. (0001842295) (Issuer)

    10/7/25 4:17:27 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MAZE
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Maze Therapeutics Inc.

    SCHEDULE 13G/A - Maze Therapeutics, Inc. (0001842295) (Subject)

    11/14/25 4:04:27 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Maze Therapeutics Inc.

    SCHEDULE 13G/A - Maze Therapeutics, Inc. (0001842295) (Subject)

    11/14/25 12:49:29 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Maze Therapeutics Inc.

    SCHEDULE 13G/A - Maze Therapeutics, Inc. (0001842295) (Subject)

    11/13/25 4:10:25 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MAZE
    Leadership Updates

    Live Leadership Updates

    View All

    Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

    First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD); topline data for initial patients expected by the end of Q1 2026 Strong balance sheet with $383.9 million in cash, cash equivalents and marketable securities following oversubscribed private placement; cash runway into 2028 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developin

    11/6/25 4:01:00 PM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors

    SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (NASDAQ:MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the Board. "I am honored to assume the role of Chairman of the Board at this pivotal moment for Maze Therapeutics," said Mr. Hoppenot. "With encouraging first-in-human data for MZE782, an oversubscribed $150 million private placement, and important clinical milestones ahead, including the advancement of M

    10/6/25 7:00:50 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $MAZE
    Financials

    Live finance-specific insights

    View All

    Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)

    Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications of PKU and CKD Dose-dependent urinary amino acid excretion demonstrated across all SAD and MAD cohorts, including up to a 42-fold increase in urinary phenylalanine (Phe) excretion, a well-validated biomarker for PKU and predictive for CKD Dose-dependent initial eGFR dip similar to SGLT2 inhibitors observed, supporting a potential kidney protective effect in CKD Well tolerated across all doses with an excellent safety profile and no serious adverse events observed Phase 2 trials in both PKU and CKD expected to initiate in 2026 Maze to hos

    9/11/25 7:30:00 AM ET
    $MAZE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care